Literature DB >> 17306793

Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study.

Meike Trieschmann1, Stephen Beatty, John M Nolan, Hans Werner Hense, Britta Heimes, Ulrike Austermann, Manfred Fobker, Daniel Pauleikhoff.   

Abstract

Macular pigment (MP), consisting of lutein (L) and zeaxanthin (Z), is believed to protect the retina from photo-oxidative damage. The current study investigates, in terms of MP optical density (MPOD) and serum concentrations of its constituent carotenoids, response to supplemental L and Z, and co-antioxidants. An intervention (I) group, consisting of 108 subjects (mean [+/-SD] age: 71.5 [+/-7.1] years), of which 92.6% exhibited features of age-related macular degeneration (AMD), received a daily supplement consisting of 12 mg L and 1 mg Z, both provided as ester 120 mg vitamin C, 17.6 mg vitamin E, 10 mg zinc, 40 microg selenium (Ocuvite Luteintrade mark) for a period of 6 months. MPOD was measured, by 2-wavelength autofluorescence (AF), on five occasions during the period of supplementation, and once again 3 months following discontinuation of the supplement. A control (C) group of 28 subjects (mean [+/-SD] age: 71.0 [+/-8.1] years), who received no dietary supplementation or modification, was examined at baseline and once again after a mean of 29.4 (+/-9.3) weeks. At baseline, mean (+/-SD) MPOD (at 0.5 degrees) was 0.504 (+/-0.197) and 0.525 (+/-0.189) in the I and C groups, respectively. There was a statistically significant increase in MPOD (at 0.5 degrees) for the I group (0.1 [+/-0.009]; p<0.0008), whereas no significant increase was seen in the C group (0.03 [+/-0.02]; p>0.05), over the period of supplementation. In order to classify supplemented subjects into quartiles, in terms of MPOD response, we calculated the difference between MPOD (at 0.5 degrees) at visit 6 and at baseline (visit 1). Quartile 1 (the "non-responder" quartile) displayed no increase in MPOD (at 0.5 degrees), in spite of rises seen in serum concentrations of L and Z. The three "responder" quartiles reached similar final plateaus of MPOD (at 0.5 degrees), reflected in final mean (+/-SEM) values of 0.59 (+/-0.04) optical density unit (ODU), 0.64 (+/-0.03) ODU and 0.64 (+/-0.03) ODU for quartiles 2, 3 and 4, respectively. Subjects with low baseline MPOD were more likely to exhibit a dramatic rise in MPOD, or to exhibit no rise in MPOD, in response to supplements than subjects with medium to high baseline MPOD values. Supplementation with 12 mg L and 1 mg Z, combined with co-antioxidants, resulted in an increase of MPOD at 0.5 degrees eccentricity in a majority of subjects, including those afflicted with AMD. However, there remains a substantial proportion of subjects for whom, in spite of rises in serum concentrations of L and Z in these subjects, MPOD augmentation in response to supplemental L, Z and co-antioxidants could not be detected over the study period, thus indicating that intestinal malabsorption of these carotenoids is not responsible for the lack of a macular response to such supplements. Further, our results suggest that saturable mechanisms play a role in the retinal capture and/or stabilisation of the macular carotenoids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17306793     DOI: 10.1016/j.exer.2006.12.010

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  58 in total

1.  Macular pigment density changes in Japanese individuals supplemented with lutein or zeaxanthin: quantification via resonance Raman spectrophotometry and autofluorescence imaging.

Authors:  Masaki Tanito; Akira Obana; Yuko Gohto; Shigetoshi Okazaki; Werner Gellermann; Akihiro Ohira
Journal:  Jpn J Ophthalmol       Date:  2012-06-15       Impact factor: 2.447

2.  Macular pigment density at the site of altered fundus autofluorescence.

Authors:  Simon Paul Rothenbuehler; Ute E K Wolf-Schnurrbusch; Sebastian Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09-28       Impact factor: 3.117

3.  Macular response to supplementation with differing xanthophyll formulations in subjects with and without age-related macular degeneration.

Authors:  David I Thurnham; John M Nolan; Alan N Howard; Stephen Beatty
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-14       Impact factor: 3.117

Review 4.  Lutein and Zeaxanthin Isomers in Eye Health and Disease.

Authors:  Julie Mares
Journal:  Annu Rev Nutr       Date:  2016-07-17       Impact factor: 11.848

Review 5.  [Vitamins for the eyes? Risks and opportunities for physician and patient].

Authors:  R Grossklaus; K J Henning
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

6.  The use of heterochromatic flicker photometry to determine macular pigment optical density in a healthy Australian population.

Authors:  Robin G Abell; Alex W Hewitt; Marko Andric; Penelope L Allen; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

7.  [The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study].

Authors:  M Zeimer; H W Hense; B Heimes; U Austermann; M Fobker; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2009-01       Impact factor: 1.059

8.  Resonance Raman imaging of macular pigment distributions in the human retina.

Authors:  Mohsen Sharifzadeh; Da-You Zhao; Paul S Bernstein; Werner Gellermann
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  2008-04       Impact factor: 2.129

9.  Effect of 1-year lutein supplementation on macular pigment optical density and visual function.

Authors:  Yuzuru Sasamoto; Fumi Gomi; Miki Sawa; Motokazu Tsujikawa; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-18       Impact factor: 3.117

Review 10.  Measuring macular pigment optical density in vivo: a review of techniques.

Authors:  Olivia Howells; Frank Eperjesi; Hannah Bartlett
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.